Exact Sciences to Participate in June Investor Conferences

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will participate in three investor conferences during June to highlight the company’s commercial strategy that’s driving the strong early growth of Cologuard.

Kevin Conroy, the company’s chairman and chief executive, will make Exact Sciences’ presentation at the Jefferies 2015 Healthcare Conference in New York at 9 a.m. ET on Thursday, June 4.

Mr. Conroy will make the company’s presentation at the William Blair 35th Annual Growth Stock Conference in Chicago at 10:40 a.m. CT on Wednesday, June 10.

Maneesh Arora, the company’s chief operating officer, will participate in a fireside chat at the Goldman Sachs 36th Annual Global Healthcare Conference in Rancho Palos Verdes, Calif., at 9:20 a.m. PT on Thursday, June 11.

A live webcast of each presentation will be available through the company’s website at www.exactsciences.com. Archived webcasts will be available following the conclusion of the presentation.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on gastrointestinal cancers. The company’s noninvasive colorectal cancer screening test, Cologuard, is the first and only FDA-approved stool-based DNA test. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company’s website at www.exactsciences.com.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, our ability to secure favorable reimbursement rates from Medicare and other third-party payors, our estimates of the available market size and our potential penetration, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150526006205/en/

Exact Sciences Corp.
J.P. Fielder
Senior Director, Corporate Communications
608-210-5220
[email protected]

Source: Exact Sciences Corp.

You May Also Be Interested In

• Exact Sciences (EXAS) PT Raised to $84 at Baird
• Bragar Eagel & Squire, P.C. Is Investigating Zoetis, and Morgan Stanley and Encourages Investors to Contact the Firm
• Crypto Hub Announces Partnership with Areon Network, Becoming the First Official Areon Launchpad